Sunday 18 October 2026
Export ABVC’s income statement to Excel — free account
ABVC BioPharma, Inc.
ABVC Healthcare Biotechnology
ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023. In the quarter to June 2026, revenue grew 66,233.3%, EPS grew 76.9% and free cash flow grew 72.7%, each against the same quarter a year earlier.
0.92
0.01
−1.08%
Follow ABVC
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Sep '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 6 | 3 | 3 | 5 | 2 | — | — | — | — |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
— | 13.52 | 34.12 | 19.59 | 238.71 | 208.14 | 108.98 | 63,310.91 | — | — |
Altman Z-Score |
— | (14.88) | (14.59) | (11.58) | 4.23 | 1.41 | 0.73 | 15.70 | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
— | (37.70) | (36.21) | (30.50) | (10.95) | (11.06) | (16.45) | (21.86) | — | — |
Beneish M-Score |
— | (3.98) | — | (5.43) | (3.14) | (5.31) | 70.57 | — | — | — |
P/Operating CF |
— | (9.81) | (12.09) | (41.20) | (33.64) | (45.96) | (51.12) | 1,560.31 | — | — |
P/B ratio |
— | 9.51 | 4.15 | 5.87 | 9.58 | 37.77 | 0.00 | 0.00 | — | — |
Price to Tangible BV |
— | 10.45 | 4.38 | 5.99 | 9.65 | 38.71 | 0.00 | 0.00 | — | — |
EV/Sales |
— | 15.10 | 51.06 | 21.88 | 226.39 | 208.79 | 109.75 | 63,320.35 | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | (4.25) | (1.86) | (2.87) | (10.60) | (22.10) | (24.57) | (464.09) | — | — |
EV/FCF |
— | (4.19) | (1.85) | (2.82) | (10.58) | (22.10) | (24.57) | (464.09) | — | — |
Quick Ratio |
0.23 | 0.32 | 0.26 | 0.42 | 1.92 | 1.10 | 0.07 | 0.03 | 0.60 | 78.94 |
Current Ratio |
0.41 | 0.33 | 0.27 | 0.54 | 2.07 | 1.27 | 0.13 | 0.05 | 0.60 | 78.94 |
Net Debt/EBITDA |
0.21 | 0.21 | 0.12 | 0.10 | 0.57 | 0.28 | (0.03) | (0.02) | (0.25) | 0.05 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 22.61% | 3.59% | 5.14% | 41.99% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | (2.00) | (0.06) | (0.63) | 0.00 |
Asset Turnover |
0.00 | 0.07 | 0.02 | 0.08 | 0.03 | 0.05 | 0.11 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.38 | 0.37 | 0.54 | 0.45 | 0.59 | 0.47 | 0.86 | 0.16 | 0.35 | 0.39 |
Capex/Depreciation |
0.00 | 0.00 | (0.06) | (5.03) | (1.46) | 0.00 | 0.00 | 0.00 | — | — |
Interest Coverage |
(17.19) | (5.70) | (5.15) | (51.41) | (51.52) | (21.00) | (7.18) | (6.02) | (39.99) | (53.28) |
| (112.81%) | (495.87%) | (346.94%) | (271.31%) | (222.66%) | (771.78%) | 133.27% | 157.11% | 269.39% | 104.78% | |
| (55.30%) | (63.99%) | (89.70%) | (141.11%) | (101.47%) | (105.65%) | (56.60%) | (129.91%) | (157.20%) | (277.73%) | |
ROIC |
(37.54%) | 0.00% | (924.61%) | (534.12%) | (333.03%) | (1,864.65%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(86.22%) | 126.80% | 200.94% | 828.45% | (286.11%) | (531.15%) | 67.25% | 56.25% | 241.50% | (149.71%) |
Average Days of Receivables |
— | 827.34 | 1,819.25 | 322.06 | 437.12 | 229.05 | 159.59 | 2,033.57 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 35.18% | 697.44% | 277.74% | 282.12% | 113.81% | 149.44% | 14,124.29% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 987.99% | 3,644.49% | 1,351.24% | 3,106.49% | 1,743.35% | 440.62% | 23,107.14% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 544.25% | 121.98% | 725.59% | 1,491.51% | 858.59% | 3.18% | 411.43% | 0.00% | 0.00% |
Graham Net Nets |
— | (0.67) | (0.94) | (0.18) | 0.03 | (0.03) | (0.08) | (0.03) | — | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.87 | 23.70 | — | — |
Earnings Yield |
— | (66.10%) | (204.17%) | (86.67%) | (15.01%) | (9.58%) | (5.00%) | (1.51%) | — | — |
Free Cash Flow Yield |
— | (26.64%) | (80.96%) | (39.57%) | (8.97%) | (4.54%) | (4.10%) | (0.22%) | — | — |
Revenue per Share |
0.00 | 0.04 | 0.04 | 0.31 | 0.14 | 0.25 | 0.40 | 0.01 | 0.00 | 0.00 |
Operating CF per Share |
(0.15) | (0.15) | (0.97) | (2.34) | (3.03) | (2.31) | (1.79) | (0.78) | (1.25) | (1.35) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.04) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.15) | (0.15) | (0.97) | (2.37) | (3.04) | (2.31) | (1.79) | (0.78) | (1.25) | (1.35) |
Cash per Share |
0.07 | 0.08 | 0.18 | 0.46 | 2.66 | 2.54 | 0.09 | 0.21 | 0.08 | 0.17 |
Shareholders Equity per Share |
0.66 | 0.06 | 0.29 | 1.02 | 3.54 | 1.35 | (0.07) | (4.60) | (1.48) | (1.18) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.66 | 0.06 | 0.29 | 1.02 | 3.54 | 1.35 | (0.07) | (4.60) | (1.48) | (1.18) |
Free Cash Flow |
(2.99) | (1.81) | (4.21) | (7.52) | (7.62) | (4.56) | (3.13) | (0.90) | (1.49) | (1.60) |
Working Capital |
(3.66) | (4.38) | (4.45) | (2.56) | 3.96 | 1.33 | (5.94) | (10.42) | (1.76) | 2.72 |
Capital Expenditures |
— | — | (0.02) | (0.12) | (0.02) | — | — | — | — | — |
Net Current Asset Value |
(5.26) | (4.64) | (4.87) | (3.36) | 2.83 | (2.77) | (6.17) | (10.71) | (1.76) | (1.39) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
— | 0.00 | 0.14 | 0.12 | 0.05 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.04 | 0.39 | 0.67 | 0.04 | 0.02 | 0.07 | 0.11 | 0.09 | — | — |
Cash ROIC |
(20.33%) | (109.47%) | (205.31%) | (159.84%) | (48.99%) | (44.36%) | (1,101.37%) | 18.79% | 268.30% | 134.55% |
Accounts Receivable Turnover |
— | 0.53 | 0.19 | 1.51 | 0.98 | 1.58 | 4.06 | 0.01 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.80 | 0.95 | 0.00 | — | — |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.39 | 28.77 | 0.00 | 176.48 | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 448.93 | 435.82 | 0.00 | — | — |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 1,860.78 | 0.00 | 0.00 | 2.56 | — | — |
Average Receivables |
— | 0.96 | 0.81 | 0.64 | 0.36 | 0.30 | 0.17 | 1.29 | 2.55 | 1.28 |
Average Payables |
— | — | — | — | — | 0.02 | 0.02 | — | — | — |
Average Inventory |
— | — | — | — | 0.01 | 0.00 | — | 0.00 | — | — |
Average Assets |
14.30 | 7.66 | 8.68 | 11.64 | 12.65 | 9.27 | 6.43 | 4.29 | 2.70 | 1.47 |
Average Common Equity |
7.01 | 0.99 | 2.24 | 6.05 | 5.77 | 1.27 | (2.73) | (3.55) | (1.57) | (3.89) |
Columns are period end dates · fundamentals updated 28 Sep 2026